Pharmacovigilance Trends in Adverse Drug Reaction (ADR) Reporting in India

Authors

  • P. Sravani Pharm D V/VI Year Student, Koringa College of Pharmacy, Kankinada.
  • S.Naga Subramanyam Professor and HOD of Koringa College of Pharmacy, Department of Pharmacy Practice, Kakinada.
  • Majjari. Venkata Padma Assistant Professor, Department of Pharmacy, Koringa College of Pharmacy, Kankinada.
  • Sanginidi Indu Harini Assistant Professor, Department of Pharmacy, Koringa College of Pharmacy, Kankinada.

Keywords:

Pharmacovigilance Programme of India (PvPI), Adverse Drug Reaction, (ADR) reporting, Drug safety surveillance, COVID-19 pandemic, Digital health reporting tools, Regulatory challenges in India

Abstract

Pharmacovigilance in India has grown rapidly over the past decade, driven by the establishment of the Pharmacovigilance Programme of India (PvPI), increasing public health initiatives, and evolving regulatory requirements. This review explores trends in adverse drug reaction (ADR) reporting in India, the impact of the COVID-19 pandemic, digital reporting innovations, and remaining challenges. While ADR reporting volumes have increased significantly, persistent under-reporting, uneven data quality, and regional disparities remain key concerns. Enhanced active surveillance, regulatory harmonization, and patient-centric digital tools are essential to sustain and strengthen pharmacovigilance in India.

Downloads

Download data is not yet available.

References

Indian Pharmacopoeia Commission. Pharmacovigilance Programme of India (PvPI): Annual report 2023–2024. Ghaziabad: Indian Pharmacopoeia Commission; 2024.

Thakare VM, Patil SP, Deshmukh YA, Kulkarni RD. Trends in adverse drug reaction reporting in India. Indian J Pharmacol. 2023;55(4):210–218.

Central Drugs Standard Control Organization (CDSCO). Guidance document on good pharmacovigilance practices. New Delhi: Ministry of Health and Family Welfare; 2020.

Hegde M, Rao S, Kulkarni V, Shetty R. Pharmacovigilance in the era of COVID-19: lessons from India. J Clin Pharm Ther. 2022;47(5):1234–1242.

World Health Organization–Uppsala Monitoring Centre. Annual VigiBase summary report 2024. Uppsala: WHO-UMC; 2024.

Mishra A, Verma R, Singh D, Patel K. Impact of digital tools on adverse drug reaction reporting in India. Int J Pharm Sci Res. 2024;15(2):567–576.

Government of India. New drugs and clinical trials rules, 2019. New Delhi: Ministry of Health and Family Welfare; 2019.

Sharma S, Gupta N, Mehta P, Verma A. Evaluation of pharmacovigilance awareness among healthcare professionals in India. Asian J Pharm Clin Res. 2023;16(1):89–95.

Singh P, Kaur R, Malhotra S. Active surveillance and signal detection in Indian pharmacovigilance. Ther Adv Drug Saf. 2024;15:1–10.

World Health Organization. Pharmacovigilance: ensuring the safe use of medicines. WHO Technical Report Series. Geneva: World Health Organization; 2022.

Published

2025-12-31

How to Cite

P, S., S, N. S., Majjari, V. P., & Sanginidi, I. H. (2025). Pharmacovigilance Trends in Adverse Drug Reaction (ADR) Reporting in India. Biospecia, 1(1), 4–5. Retrieved from https://uniquepubinternational.com/journals/index.php/biospecia/article/view/163

Issue

Volume 1, Issue 1, 2025

Section

Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.